MMJ Phytotech Limited (ASX:MMJ)
has announced it received international government approval to start Phase 2 of its clinical trial in treating multiple sclerosis (MS) patients.
The medical cannabis company’s Israeli-based subsidiary, received approval from the Ministry of Health and Helsinki (IRB of Sheba Clinical Site) to study 70 MS patients with their drug.
The study will take place at the MS Center, at the largest hospital in Israel, the Sheba Hospital.
The study will measure the safety and efficacy of Phytotech’s PTL201 capsules in treating debilitating MS symptoms
MMJ Phytotech says, the success of Phase 2 of the trial will be a major step toward the commercial development of its drug.
Shares in MMJ Phytotech Limited (ASX:MMJ)
has last traded 2.56% lower to 38 cents.